ORGO — Organogenesis Holdings Inc.

Summary of Organogenesis Holdings, Inc. Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Net Product Revenue: $225.1 million, up 78% year-over-year and 50% sequentially, exceeding guidance of $162 million to $187 million.
• Advanced Wound Care Revenue: $217.2 million, up 83% year-over-year.
• Surgical & Sports Medicine Revenue: $7.9 million, down 2% year-over-year.
• Gross Profit: $175.2 million, representing 78% of net product revenue, up from 75% the previous year.
• Operating Income: $63.3 million, up 519% from $10.2 million year-over-year.
• GAAP Net Income: $43.7 million, compared to $7.7 million last year.
• Adjusted EBITDA: $84.2 million, or 37% of total revenue, compared to 14% last year.
• Cash Position: $94.3 million in cash and equivalents, down from $136.2 million year-over-year, with no debt obligations.

2. Strategic Updates and Business Highlights

• Advanced Wound Care Growth: Significant growth attributed to strong execution and customer relationships.
• Regulatory Changes: Positive outlook on CMS's reimbursement policy changes favoring PMA products, which Organogenesis supports.
• New Manufacturing Facility: Progress on a state-of-the-art facility in Rhode Island to enhance production capabilities.
• ReNu Program: Initiated rolling BLA submission expected to complete in the first half of 2026, targeting knee osteoarthritis treatment.

3. Forward Guidance and Outlook

• 2026 Revenue Forecast: Anticipated decline of 25% to 38% year-over-year, with Q1 expected to see a 50% decline due to clinician confusion from recent CMS comments.
• Second Half Recovery: Expected sequential growth in Q2 and strong performance in Q3 and Q4, leading to positive adjusted EBITDA and high teens margins in Q4.

4. Challenges and Points of Concern

• Clinician Confusion: Recent CMS comments have led to significant confusion impacting the utilization of PMA products.
• Market Dynamics: The operating environment remains uncertain, with potential competitive pressures and pricing tactics affecting revenue.
• Short-term Headwinds: Anticipated challenges in the first half of 2026 due to the adjustment period following CMS's policy changes.

5. Notable Q&A Insights

• Inventory Pull-Forward: Management indicated minimal inventory pull-forward ahead of reimbursement changes, emphasizing actual patient demand.
• Competitive Landscape: Early signs of changing competitive dynamics, with some smaller competitors potentially exiting the market.
• Management Confidence: Despite challenges, management expressed optimism about gaining market share and overcoming clinician confusion as the year progresses.

Overall, while Organogenesis achieved record financial results in Q4 2025, the company faces significant challenges in 2026 due to regulatory changes and market confusion, with a cautious yet optimistic outlook for recovery in the latter half of the year.